Facial Pigmentation Treatment by Injection Tranexamic acid intradermally in ski
Phase 2
- Conditions
- Health Condition 1: L811- Chloasma
- Registration Number
- CTRI/2022/02/040450
- Lead Sponsor
- Dr Meghna Khatri
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Patients willing to participate in the study.
2. Patients of either sex with clinical features of melasma.
3. Patients in the age group of 18-60 years.
Exclusion Criteria
1.Patients below the age of 18 years and above the age of 60 years.
2.Patients having any other hyperpigmented disorder on the face.
3.Patients not willing to participate in the study.
4.Pregnant or lactating females.
5.Patients with bleeding disorders.
6.Patients on anticoagulant therapy.
7.Patients having hypersensitivity to tranexamic acid.
8.Patients having bilaterally asymmetrical pigmentation.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Reduction in Melasma Area Severity Index (MASI) will be estimated by clinical examination, photographically and dermoscopically at baseline and then further change in MASI score will be estimated at 2 weeks, 4 weeks, 6 weeks and then after 3 months.Timepoint: Patient will be assessed clinically, photographically, dermoscopically and by patient satisfaction score at baseline, and at every visit i.e. after 2 weeks, 4 weeks and 6 weeks till completion of treatment. Apart from that patient will be reassessed by same parameters after 3 months.
- Secondary Outcome Measures
Name Time Method Patient will be assessed dermoscopically for pigment reduction at baseline and then at 2 weeks, 4 weeks, 6 weeks and then after completion of treatment i.e. 3 months.Timepoint: Patient will be assessed clinically, photographically, dermoscopically and by patient satisfaction score at baseline, and at every visit i.e. after 2 weeks, 4 weeks and 6 weeks till completion of treatment. Apart from that patient will be reassessed by same parameters after 3 months.